A nearly 14-month improvement in progression-free survival is more than impressive — it’s paradigm shifting.
This clip breaks down the DESTINY-Breast09 trial design, why the results were anticipated based on second-line data, and how moving T-DXd into the first-line setting changes the HER2-positive treatment landscape.
DESTINY-Breast09 Explained: Why 40 Months PFS Matters
You may also like
Recommended Videos
